“…For example, when present as the dominant species in a 3:1:1 molar ratio, they accelerate barrier recovery after acute abrogation in comparison to vehicletreated sites [4,14]. Two pseudo-Cer, i.e., N-(3-hexadecyloxy-2-hydroxypropyl)-N-2-hydroxyethylhexadecanamide (PC-104) and a similar structural compound, N-(2-hydroxyethyl)-2-pentadecanolylhexadecanamide (Bio391), can form lamellar/multilamellar structures in vitro with cholesterol and free fatty acids [15][16][17]. Accordingly, the cutaneous symptoms of atopic dermatitis appear to improve in patients treated with pseudo-Cer (PC-104 and others)-containing mixtures [4,18,19].…”